The highly purified, inactivated candidate for VLA1601 achieved the primary endpoint of the study because of a favorable safety profile for all doses tested and vaccination schedules.
VLA1601 was also immunogenic in all treatment groups, and induced both Zika's vaccine and vaccine antibodies with the kinetic properties expected in the inactivated vaccine with a worldwide adjuvant with aluminum adjuvant. Seroconversion rate reached 35.7. On 85.7% (continuous data analysis up to 56 days).
The Phase 1 study was designed to assess safety and immunogenicity. It is co-funded by Emergent and Valneva. The framework is the exclusive worldwide license agreement that was completed in July 2017. The agreement contains pre-defined opt-in rights for Emergent after the first phase.
MUDr. Wolfgang Bender, PhD, said, "We are pleased with the progress of this promising vaccine candidate for the prevention of Zico virus infections and their serious effects during pregnancy." "An excellent safety profile encourages further optimization of the immune response generated to meet unmet medical needs in the most vulnerable populations.
Kelly Lyn Warfield, PhD, vice president of research and development of vaccines and antiinfectives at Emergent BioSolutions, added: "Focusing on the development of preventive and therapeutic strategies for the spread of infectious diseases is part of Emergent's broader mission of bringing life to the table to protect and improve. impact on global public health through our work. "